Ipinapakita ng pagsasaliksik sa bagong Cleveland Clinic sa kauna-unahang pagkakataon na ang inaprutinib na inaprubahan ng FDA para sa lymphoma at leukemia ay maaari ring makatulong na gamutin ang pinakakaraniwan at nakamamatay na mga tumor sa utak, at maaaring magamit sa isang araw sa mga pasyente na may glioblastoma At mapabuti ang mga rate ng kaligtasan.
Ayon sa ulat ng American Brain Tumor Association, ang kaligtasan ng buhay ng glioblastoma ay napakababa, at ang panggitna kaligtasan ng buhay ng mga pasyente na tumatanggap ng karaniwang paggamot ay mas mababa sa 15 buwan. Ang Glioblastoma ay ang pinaka nakamamatay na pangunahing tumor sa utak at lubos na lumalaban sa kasalukuyang paggamot. Mayroong isang kagyat na pangangailangan na magbigay sa mga pasyenteng ito ng mga bagong paggamot sa lalong madaling panahon.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain mga bukol in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
